IPCALAB

IPCA Laboratories Ltd – Company Overview

Formulations (Finished Dosage Forms) Contributes around 65–70% of total revenue. Strong domestic presence with brands in cardiology, pain management, anti-malarial, and anti-infective segments. Key brands include Lariago, Zerodol, Tenolol, and Malirid. APIs (Bulk Drugs) IPCA is a major global supplier of APIs such as Atenolol, Chloroquine Phosphate, Hydroxychloroquine, and Metoprolol. Its API segment enjoys leadership in anti-malarial and cardiovascular categories. Global Presence Exports to over 100 countries including Europe, Africa, and Latin America. Approximately 45% of total revenue comes from international markets. Supplies to leading global pharmaceutical companies under long-term supply contracts. Financial Snapshot Market Capitalization: Around ₹33,000 crore. Current Share Price: Approximately ₹1,310–1,320. P/E Ratio: Around 36x. ROE: ~12–14%. Debt-to-Equity Ratio: 0.02 (virtually debt-free). Dividend Yield: ~0.6%. In recent quarters, IPCA reported steady growth in both formulations and API segments, aided by strong demand in anti-malarial and chronic therapies. Margins have improved due to operating leverage and cost efficiency.